๐ Crinetics $CRNX nearly doubles +99% premarket โ Vertex drops $10B to scoop up rare hormone therapies
Vertex Pharmaceuticals announced an all-cash buyout of Crinetics Pharmaceuticals at $85/share, valuing the rare-disease biotech at ~$10 billion. The deal hands Vertex two oral therapies targeting rare hormonal diseases and is expected to close in Q3 2026. Crinetics shareholders are cashing in on one of the biggest pharma M&A premiums of the year. Not financial advice. Which biotech do you think gets acquired next?
โก 27 buzzing
363 views
๐ 0 subscribed